Clinical trial · people

Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesity

Checked against the paper Clinical trialPublished by PepVault

The takeaway

In a small, uncontrolled trial, setmelanotide lowered BMI and hunger in people whose obesity followed hypothalamic damage, and nausea and skin darkening were common.

Kind
Clinical trial
Studied in
People
Number studied
18
Published
2024
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether daily setmelanotide could lower body mass index in people whose obesity followed damage to the hypothalamus, a part of the brain.

How the study was done

A phase 2, open-label trial at 5 US centers in 18 patients aged 6 to 40 years with obesity after a hypothalamic injury or a treated non-cancerous tumor in that area. Everyone got daily setmelanotide shots under the skin, raised up to 3.0 mg, for 16 weeks, with no placebo group. Results were compared with a historic rate of under 5% reaching the goal in this group.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

16 of 18 patients (89%) finished the trial and lowered their BMI (body mass index, a measure of weight for height) by at least 5%. Mean BMI fell by 15% (SD 10). Among patients aged 12 or older, hunger scores fell by a mean 45%. Common side effects were nausea (61%), vomiting (33%), skin darkening (33%) and diarrhea (22%). In a follow-on study, 12 patients treated for at least 12 months had a mean BMI change of -26% (SD 12) from the start.

What it doesn’t show

This was a small, 16-week trial with no placebo group, and everyone knew they were getting the drug, so results were judged against a historic rate rather than a direct comparison group. It was funded by Rhythm Pharmaceuticals.

The paper

Roth et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024.

The compound

More studies on Setmelanotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo